Introduction: Peripheral artery disease (PAD) reduces tissue perfusion and causes ischemia, conditions in which hypoxia-responsive pathways have an important adaptive role. Hypoxia- inducible factor 1-alpha (HIF-1α), a central regulator of this response, is tightly controlled by prolyl hydroxylase domain protein 2 (PHD2), encoded by EGLN1. Here, we used an RNA-targeting CRISPR-Cas13d system to downregulate EGLN1 in human umbilical vein endothelial cells (HUVECs) under normoxia and hypoxia. Methods: A PHD2-knockdown (PHD2-KD) HUVEC line was generated by lentiviral delivery of an EGLN1-targeting RNA guide, alongside non-transduced (CTRL) and non-targeting gRNA (NTG) control lines. Molecular and functional assays assessed hypoxia-related signaling, metabolic activity, migration, and sprouting responses under normoxia and hypoxia. results: PHD2-KD HUVECs showed significantly increased VEGFA expression under both normoxia and hypoxia, at the mRNA level (7.0-fold and 5.4-fold, respectively) and protein level (6.6-fold and 9.4-fold, respectively). At early time points (3–12 h), HIF-1α gene and protein levels were elevated, accompanied by reduced inflammatory cytokine levels, with TNF-α becoming undetectable after 48 h. Functionally, PHD2-KD cells showed enhanced proliferation, faster wound closure (2.0-fold under normoxia and 2.2-fold under hypoxia), and increased sprouting activity, with up to 5.4-fold more sprouts per bead and sprouts up to 2.5-fold longer than controls. Results: Western blotting confirmed a marked reduction in PHD2 protein abundance in PHD2-KD cells relative to both CTRL and NTG cells. PHD2-KD HUVECs exhibited increased VEGFA transcript levels (6.5-fold under normoxia and 5.3-fold under hypoxia) and secreted VEGF concentrations (6.6-fold and 9.4-fold, respectively), together with early increases in HIF1A transcript and HIF-1α protein levels and lower TNF-α concentrations. Functional assays showed higher metabolic activity, faster wound closure (2.0-fold under normoxia and 2.2-fold under hypoxia), and enhanced sprouting, with up to 7.2-fold more sprouts per bead and sprouts up to 2.7-fold longer than those formed by CTRL. Discussion: CRISPR-Cas13d-mediated EGLN1 targeting reduced PHD2 protein abundance and was associated with higher endothelial metabolic activity, faster wound closure, enhanced sprouting behavior, and lower TNF-α secretion. Conclusion: CRISPR-Cas13d-mediated downregulation of EGLN1/PHD2 was associated with increased pro-angiogenic signaling and improved angiogenesis-related endothelial responses in vitro, supporting RNA-targeting strategies to modulate hypoxia-responsive pathways.